ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

The Microbiome Links Seres And Nestlé …

by Michael McCoy
January 18, 2016 | APPEARED IN VOLUME 94, ISSUE 3

Seres Therapeutics is joining with Nestlé Health Science to develop drugs that harness the gut microbiome to treat Clostridium difficile infection and inflammatory bowel disease. Seres will receive $120 million up front and could get up to $1.9 billion in total payments. In exchange it will give Nestlé rights outside the U.S. and North America to its lead candidate, SER-109, as well as other products. SER-109, which has completed a Phase Ib/II study, treats C. difficile infection with spores of beneficial bacteria derived from stool samples. Nestlé also invested in Seres twice last year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment